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ABSTRACT  19 
In 1973, IL-6 was identified as a soluble factor that is secreted by T cells and is important for 20 
antibody production by B cells. Since its discovery more than 40 years ago, the IL-6 pathway 21 
has emerged as a pivotal pathway involved in immune regulation in health and dysregulation 22 
in many diseases. Targeting of the IL-6 pathway has led to innovative therapeutic approaches 23 
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for various rheumatic conditions such as rheumatoid arthritis, juvenile idiopathic arthritis, 24 
adult onset Still’s disease, giant cell arteritis, Takayasu arteritis, and others such as 25 
Castleman’s disease or cytokine release syndrome. Targeting this pathway [Au:OK?Yes] has 26 
also identified avenues for potential expansion into several other indications, such as uveitis 27 
and neuromyelitis optica. To mark the tenth anniversary of anti-IL-6-receptor therapy 28 
worldwide, we discuss the history of research into IL-6 biology and the development of 29 
therapies that target IL-6 signalling, including the successes and challenges and with an 30 
emphasis on rheumatic diseases. 31 
  32 
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 33 
[H1] Introduction 34 
 35 
Cytokine inhibitors have transformed the outcome of many chronic inflammatory diseases. A 36 
decade has passed since the approval of anti-IL-6-receptor (anti-IL-6R) therapy, which is 37 
now used worldwide in various rheumatic conditions such as rheumatoid arthritis (RA), 38 
juvenile idiopathic arthritis (JIA), adult onset Still’s disease (AOSD), giant cell arteritis 39 
(GCA) and Takayasu arteritis, as well as other conditions such as Castleman’s disease and 40 
cytokine release syndrome (CRS). To mark this anniversary, we discuss the 40-year history 41 
of translational research into IL-6 biology and the subsequent development of therapies 42 
targeting this pivotal cytokine pathway, which helps to inform future biologic and clinical 43 
research. [Au: Edits have been made to clarify this introductory text, to break up a very 44 
long sentence and to avoid repeating wording used in the abstract – edited text 45 
OK?Yes]  46 
 47 
[H1] From signalling to drug discovery  48 
The journey from the discovery of IL-6 biology to the development of an IL-6 pathway 49 
inhibitor as a potential treatment for various diseases started coincidentally with the meeting 50 
of two research groups in Japan. In 1973, researchers at Osaka University led by Tadamitsu 51 
Kishimoto first reported that a soluble factor secreted by T cells was important for antibody 52 
production by B cells (Figure 1); subsequently, this soluble factor was cloned as IL-6, which 53 
turned out to have various roles in several autoimmune diseases.1, 2 At the same time, 54 
researchers at Chugai Pharmaceutical were exploring new avenues for drug development for 55 
autoimmune diseases. In the late 1980s, the two groups started to collaborate to further 56 
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advance the understanding of the biological role of IL-6 in various autoimmune diseases and 57 
the development of IL-6 inhibitors as treatment options. To increase their collaborative 58 
potential, the two research groups even moved to adjoined laboratories at Osaka University. 59 
The university researchers led efforts to identify IL-6 signalling mechanisms and the biologic 60 
effects of IL-6, whereas the company focused on developing and characterizing IL-6 61 
inhibitors as potential new treatments for autoimmune diseases. 3-5  62 
The traditional approach of searching for small-molecule inhibitors proved challenging when 63 
the research team found that IL-6 signal transduction occurred through a hexameric high-64 
affinity complex of IL-6, IL-6R and glycoprotein 130 (gp130) (Figure 2). Moreover, both 65 
soluble IL-6R (sIL-6R) and membrane-bound IL-6R (mIL-6R) can be part of the hexameric 66 
complex; hence, the binding region of IL-6–IL-6R–gp130 was considered too complex and 67 
broad for a small molecule compound to inhibit the IL-6 signal pathway.6, 7 The 68 
aforementioned mIL-6R and sIL-6R forms are associated with so-called classical and trans 69 
signalling pathways, respectively, the details of which and corresponding avenues for drug 70 
development have been reviewed extensively elsewhere.4 Both signalling routes involve 71 
phosphorylation of Janus kinase 1(JAK1), JAK2 and tyrosine kinase 2 (TYK2) , which can 72 
also be targeted therapeutically with different molecules but are not the focus of this article.4 73 
The decision to target sIL-6R rather than IL-6 itself was made taking into consideration that 74 
concentrations of the receptor have less interpatient variability than concentrations of IL-6, 75 
potentially simplifying dose and regimen selection. 8, 9 With concurrent advances in 76 
biotechnology, the two groups decided to develop a humanized monoclonal antibody 77 
targeting IL-6R.10-12 The resulting humanized anti-IL-6R antibody, tocilizumab, binds to 78 
mIL-6R and sIL-6R and inhibits IL-6 signalling by preventing IL-6 from binding to IL-6R.11, 79 
12 The therapeutic benefit of this anti-IL6R antibody led to the development of several anti-80 
IL-6 antibodies (sirukumab, olokizumab and clazakizumab). 81 
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 82 
[H1] Initial therapeutic applications  83 
As IL-6 is well known to have various physiological roles, in considering IL-6 as a 84 
therapeutic target its homeostatic role versus its pathogenic role in various autoimmune 85 
diseases was extensively debated. 3, 4 However, utilizing cell-based assays, animal models 86 
and ex vivo serum and tissue analyses, scientists identified several candidate diseases that 87 
might benefit from the use of IL-6 inhibition (Table 1). 88 
A 1988 publication reported that IL-6 is an important growth factor in myeloma cells. 13 89 
Oncologists in France conducted an open-label clinical trial of a mouse anti-IL-6 antibody in 90 
patients with multiple myeloma, the second most common type of blood cancer after 91 
leukemia.14 Although none of the patients treated had an improved outcome or achieved 92 
remission in the initial report of the trial, post hoc analysis revealed that treatment with the 93 
anti-IL-6 antibody showed some efficacy in those patients who produced low concentrations 94 
of IL-6 .15 More than 20 years later, a clinical trial evaluated whether the addition of a 95 
different chimeric anti-IL-6 monoclonal antibody, siltuximab, to the bortezomib–melphalan–96 
prednisone regimen would be beneficial to patients with newly diagnosed multiple myeloma; 97 
however, this IL-6 inhibitor also failed to improve outcomes. 16  98 
In 1989, a publication described constitutive overproduction of IL-6 from the germinal 99 
centers of hyperplastic lymph nodes in patients with Castleman's disease, a 100 
lymphoproliferative disorder, and a correlation of serum IL-6 concentrations with clinical 101 
abnormalities.17 Consistent with these observations, transgenic mice carrying the human IL6 102 
gene, under the control of an immunoglobulin promoter, developed clinical features of 103 
Castleman’s disease including splenomegaly, lymph node enlargement, and high 104 
concentrations of IL-6 and IgG.18, 19 In a 1994 case report, administration of a mouse anti-IL-105 
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6 neutralizing antibody to a patient with Castleman's disease seemed to be therapeutically 106 
effective.20 Tocilizumab also had positive effects in a small case series of seven patients in 107 
2000 and in a multicentre prospective open-label study in 2005 that included 28 patients with 108 
Castleman's disease.21, 22 In the prospective study [Au:OK? Yes], bi-weekly treatment with 109 
tocilizumab consistently alleviated lymphadenopathy and improved all inflammatory 110 
parameters over 60 weeks.22 A double-blind placebo-controlled trial of siltuximab also 111 
showed efficacy in this indication. 23 Subsequently, tocilizumab was approved for the 112 
treatment of Castleman’s disease in Japan and siltuximab was approved for this indication in 113 
various countries.  114 
A 1995 study reported that serum concentrations of IL-6 and sIL-6R were elevated in patients 115 
with Crohn’s disease, a type of inflammatory bowel disease, and correlated with C-reactive 116 
protein levels. 24 On the basis of these observations, tocilizumab was evaluated in a phase II 117 
randomized placebo-controlled trial (RCT) with patients with active Crohn’s disease (defined 118 
as Crohn's Disease Activity Index [CDAI] score >150. 25 The primary end point, a reduction 119 
of CDAI >70 points, was met by 80% of the patients who received bi-weekly tocilizumab, 120 
compared with 31% of the placebo-treated patients, demonstrating the substantial efficacy of 121 
tocilizumab. However, the development of tocilizumab for Crohn’s disease did not proceed 122 
owing to rare reports of gastrointestinal perforations observed in concurrent clinical trials in 123 
arthritis and because of an increased understanding of the homeostatic role of IL-6 in the 124 
intestinal epithelium. 26 Together, these findings suggested that patients with Crohn’s disease 125 
might be at increased risk of potential detrimental effects of IL-6 inhibition.  126 
 127 
[H1] IL-6 inhibition in RA 128 
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The development path for an IL-6 inhibitor for the treatment of rheumatoid arthritis (RA), the 129 
most common chronic autoimmune disorder that primarily affects joints, began in the early 130 
1990s, when cell-based experiments revealed that IL-6 might be involved in osteoporosis, 131 
cartilage destruction and synovial inflammation associated with RA.27-29,30 In mouse models 132 
of collagen-induced and antigen-induced arthritis, IL-6 inhibition prevented the development 133 
of arthritis but did not ameliorate arthritis once the disease was established.31-33 In a 1993 134 
study, the administration of a mouse anti-IL-6 monoclonal antibody to patients with RA 135 
resulted in improvements of disease symptoms and laboratory measures of disease activity, 136 
although the effects were transient.34 In 2000, the efficacy and tolerability of tocilizumab was 137 
investigated in a case series of 11 patients with refractory RA; the treatment was well 138 
tolerated and led to both clinical and biochemical improvements.35 On the basis of these 139 
results, larger and confirmatory double-blind RCTs of tocilizumab were conducted in patients 140 
with refractory RA.36-40 Tocilizumab improved clinical signs and symptoms of RA, 141 
laboratory parameters and radiological manifestations, and also ameliorated the effects of RA 142 
on patient reported outcomes, activities of daily living and quality of life, when administered 143 
as monotherapy or in combination with conventional synthetic DMARDs (csDMARDs).41-45 144 
These and other studies led to tocilizumab receiving marketing authorization (Figure 1) for 145 
patients with early RA not previously treated with methotrexate and those with established 146 
RA and an inadequate response to previous treatment with DMARDs or TNF antagonists; in 147 
these patients, tocilizumab is administered in combination with methotrexate or as 148 
monotherapy if methotrexate is not tolerated or continued treatment with methotrexate is not 149 
appropriate. 150 
A notable finding of further clinical investigation in several RCTs and real-world data was 151 
that, unlike TNF inhibitors, tocilizumab monotherapy was superior to methotrexate or other 152 
csDMARDs for reducing the signs, symptoms and radiographic progression of RA. 39, 40, 46-59 153 
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In particular, a head-to-head, double-blind, double-dummy RCT found that, when used as 154 
monotherapy, tocilizumab was superior to the TNF inhibitor adalimumab in measures of 155 
disease activity and several other outcomes. 46 On the basis of these results, EULAR 156 
recommendations for the management of RA named IL-6 pathway inhibitors as one of the 157 
preferred treatment options for patients for whom methotrexate is inappropriate.60 158 
Interestingly, the clinical benefits of IL-6 inhibition might be attributable, in part, to the 159 
beneficial effects of IL-6 inhibition on bone and cartilage turnover, which are supported by 160 
data from prospective cohort studies showing that tocilizumab monotherapy achieves better 161 
repair of focal bone erosions than TNF inhibition in patients with RA.60-70 Besides promoting 162 
joint inflammation and damage through effects on chondrocytes, osteoclasts, macrophages 163 
and fibroblasts, IL-6 mediates systemic inflammation in RA. IL-6 affects T and B cell 164 
differentiation, and is the key driver of the acute phase response in RA. Key symptoms and 165 
comorbidities such as pain, fatigue, anxiety, depression, anaemia and cardiovascular disease 166 
can be mediated by IL-6 [refs 71, 72], as shown in Figure 3.  167 
Since tocilizumab was approved for RA, sarilumab, an alternative anti-IL-6R monoclonal 168 
antibody, has also demonstrated efficacy and safety and has been approved for the treatment 169 
of RA.73-75 Three other anti-IL-6 monoclonal antibodies, sirukumab, olokizumab and 170 
clazakizumab, have also been tested in clinical trials in RA. In phase III RCTs that included 171 
patients with RA refractory to treatment with csDMARD and biologic DMARDs, sirukumab 172 
was superior to placebo in improving disease activity, physical function and health related 173 
quality of life, as well as inhibiting radiographic disease progression. 76, 77 However, 174 
monotherapy with sirukumab was similar but not superior to adalimumab and efforts to 175 
obtain regulatory approval in RA were terminated. 78 Phase II trials of olokizumab 176 
demonstrated therapeutic benefit and phase III trials are ongoing.79 However, the 177 
development of clazakizumab as a treatment for RA has also been terminated. 178 
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 179 
[H1] IL-6 inhibition in JIA and AOSD  180 
JIA is a term encompassing all forms of chronic arthritis affecting children younger than 16 181 
years of age. 80 JIA exists as several different subtypes: oligoarticular JIA, polyarticular JIA, 182 
juvenile psoriatic arthritis, enthesitis-related arthritis and systemic JIA (sJIA). In sJIA, 183 
arthritis is associated with prominent systemic features, including high spiking fever, rash, 184 
serositis, and inflammatory signs. This disease is further characterized by high morbidity and 185 
mortality rates, joint destruction, functional disability, and growth retardation.80 186 
Concentrations of IL-6 are markedly elevated in the serum and synovial fluid of patients with 187 
sJIA and a vast body of evidence from cell-based experiments and animal models 188 
demonstrates that IL-6 overproduction seems to explain most, if not all, of the clinical and 189 
laboratory features of the disease including fever spikes, acute phase response, anaemia, 190 
growth retardation and systemic osteoporosis.81-85 In 2005, clinical trials of tocilizumab in 191 
patients with sJIA conducted in the UK and Japan provided proof of principle of the efficacy 192 
of IL-6 inhibition in this severe pediatric condition.86, 87 Two subsequent trials of tocilizumab 193 
in >150 children with sJIA confirmed extensive improvements in the signs and symptoms of 194 
disease following treatment with tocilizumab and demonstrated clinically relevant 195 
glucocorticoid-sparing potential of IL-6 inhibition.88-92 The efficacy and safety of IL-6 196 
inhibition in sJIA has also been confirmed in real-world studies.93 Reversal of sJIA-197 
associated growth retardation has also been demonstrated with IL-6 inhibition, with patients 198 
experiencing catch-up growth during treatment with tocilizumab. 92  199 
AOSD and sJIA are increasingly considered to be the same disease, with AOSD occurring in 200 
adulthood and sJIA in childhood. In a double-blind RCT of 27 patients with AOSD refractory 201 
to treatment with glucocorticoids, an ACR50 response (reflecting 50% improvement) at week 202 
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4 was achieved in ~61% of patients treated with tocilizumab, compared with ~31% of 203 
placebo-treated patients, although the difference was not statistically significant.94 Patients in 204 
the tocilizumab group also had improvements in systemic symptoms and a decreased dose of 205 
glucocorticoids compared with the placebo group. On the basis of data from this trial, 206 
tocilizumab was approved for the treatment of AOSD in Japan in 2019.  207 
Polyarticular JIA is characterized by a potentially destructive disease course. Trials of 208 
tocilizumab were undertaken in polyarticular JIA from 2009 on the basis of results obtained 209 
in RA. In a small trial in 19 patients, 100% of patients met the criteria for a good response 210 
after 48 weeks of treatment with tocilizumab.95 In a pivotal phase III trial and its subsequent 211 
long-term extension study in 188 patients, inhibition of IL-6 led to sustained and clinically 212 
meaningful improvements after 2 years and skeletal growth was also improved by treatment 213 
with tocilizumab.96, 97 Another anti-IL-6R antibody, sarilumab, is in phase II trials for 214 
polyarticular JIA.98 and sJIA99. 215 
 216 
[H1] IL-6 inhibition in SpA 217 
Seronegative spondyloarthritis (SpA) is a group of inflammatory rheumatic diseases includin 218 
ankylosing spondylitis (AS) and psoriatic arthritis (PsA) with common clinical and 219 
aetiological features such as axial and peripheral inflammatory arthritis, enthesitis and extra-220 
articular manifestations. 100 The absence of the serological markers rheumatoid factor (RF) 221 
and antibodies against cyclic citrullinated peptides differentiate SpA from RA. AS is a 222 
chronic, debilitating and gradually progressive inflammatory rheumatic disease that primarily 223 
affects the axial skeleton and sacroiliac joints but can also affect the peripheral joints. 101 224 
Serum IL-6 concentrations are elevated in patients with AS and correlate with disease 225 
activity. 102 However, tocilizumab failed to show therapeutic benefit in AS in two double-226 
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blind RCTs in 2014. 103 Sarilumab was also ineffective as a treatment for AS in a 2015 RCT. 227 
104 The conclusion from these RCTs is that IL-6 is not a therapeutic target in AS.  228 
PsA is a chronic immune-mediated disease characterized by widespread musculoskeletal 229 
inflammation and is the major comorbidity associated with psoriasis. 105 The rationale for 230 
inhibiting IL-6 in PsA was based on a small number of studies that demonstrated elevated 231 
concentrations of IL-6 in both the serum and synovial fluid of patients with PsA.106, 107 In a 232 
placebo-controlled phase II RCT, clazakizumab improved arthritis, enthesitis and dactylitis in 233 
patients with PsA but with minimal improvements in skin disease.108 Currently, development 234 
of clazakizumab for this indication seems to have been terminated. 235 
 236 
[H1] IL-6 inhibition in SLE and SSc 237 
In 1990, a study in NZB/W F1 mice, an animal model of systemic lupus erythematosus 238 
(SLE), suggested that IL-6 could have a role in the pathogenesis of immune complex-239 
mediated glomerulonephritis.109 Moreover, IL-6 concentrations are elevated in serum and 240 
urine samples from patients with SLE or lupus nephritis, and correlate with disease activity. 241 
110, 111 In an open-label phase I study in 16 patients with SLE, treatment with tocilizumab 242 
improved disease activity; notably, arthritis improved in all seven patients who had arthritis at 243 
baseline and resolved in four of them. 112, 113 Levels of anti–double-stranded DNA antibodies 244 
decreased even after adjustment for the decrease in total IgG titres following tocilizumab 245 
treatment. 112 These changes, together with a decrease in the frequency of circulating plasma 246 
cells, suggested a specific effect of IL-6 inhibition on autoantibody-producing B cells. 247 
However, further studies with sirukumab did not demonstrate a clinically meaningful benefit 248 
of IL-6 pathway inhibition in patients with lupus nephritis or SLE. 114, 115 These conflicting 249 
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results in SLE have tempered further clinical development. Whether IL-6 inhibition might be 250 
effective for some manifestations of SLE and not others requires further studies. 251 
IL-6 is also implicated in the pathogenesis of systemic sclerosis (SSc). In the bleomycin 252 
mouse model of SSc, IL-6 blockade reduced skin fibrosis, α smooth-muscle actin protein 253 
expression, hydroxyproline content, and myofibroblast counts.116 Dermal fibroblasts from 254 
patients with SSc constitutively express more IL-6 than those from healthy controls, and 255 
serum IL-6 concentrations are elevated in patients with early SSc.117, 118 In a 2010 report, 256 
softening of skin sclerosis was observed in two patients with diffuse cutaneous SSc who 257 
received tocilizumab treatment.119 In a double-blind phase II RCT in 87 patients with active 258 
diffuse SSc, fewer patients in the tocilizumab group had a decline in forced vital capacity 259 
compared with the placebo group, but improvements in skin thickening (measured by 260 
modified Rodnan skin score) with tocilizumab were not statistically significant.120 Results of 261 
a follow-up phase III double-blind, placebo-controlled trial in 212 patients with progressive 262 
SSc again showed a numerical reduction in skin score with tocilizumab at week 48 but the 263 
difference did not reach statistical significance.121 Regarding the mean change in forced vital 264 
capacity from baseline to week 48, tocilizumab performed better than placebo, suggesting a 265 
potentially clinically important effect of tocilizumab on preservation of lung function.121 266 
Studies with larger sample size will better define clinical benefit and identify specific SSc 267 
patient population for IL-6 inhibition.  268 
 269 
[H1] IL-6 inhibition in vasculitis and PMR  270 
Takayasu arteritis and GCA are chronic, potentially life-threatening, primary systemic large-271 
vessel vasculitides 122, 123. Takayasu arteritis affects the aorta and its major branches in 272 
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adolescents and young adults, whereas GCA affects large and medium-sized arteries and 273 
usually affects individuals above the age of 50 years.  274 
IL-6 has been implicated as an important factor in the pathogenesis of both GCA and 275 
Takayasu arteritis in the 1990s. First, serum level of IL-6 correlated with disease activity in 276 
both diseases.124, 125 Second, tocilizumab improved disease signs and symptoms in patients 277 
with refractory GCA or refractory Takayasu arteritis in case series. Subsequently, a single-278 
centre phase II RCT and a phase III multicenter, double-blind RCT investigated whether 279 
tocilizumab could sustain remission and enable glucocorticoid tapering.126, 127 In the phase III 280 
RCT, sustained glucocorticoid-free remission at 52 weeks was achieved in more patients 281 
treated with tocilizumab weekly (56%) or every other week (53%) (in combination with a 282 
prednisone taper over 26 weeks) than in patients who received placebo plus a prednisone 283 
taper over 26 weeks (14%) or placebo plus a prednisone taper over 52 weeks (18%).127 284 
Consequently, tocilizumab was approved for the treatment of patients with GCA by the FDA 285 
and EMA in 2017, making this the first drug approved for the treatment of GCA other than 286 
glucocorticoids. A phase III trial evaluating the efficacy and safety of sarilumab in patients 287 
with GCA is currently ongoing.128 288 
In Takayasu arteritis, a double-blind RCT in Japan showed that, compared with placebo, 289 
tocilizumab treatment prolonged the time to relapse during glucocorticoid tapering.129 290 
Although the primary end point of the study was not met, tocilizumab has been approved in 291 
Japan for the treatment of Takayasu arteritis refractory to existing therapies.  292 
Polymyalgia rheumatica (PMR) is a disease closely related to GCA, with stiffness and muscle 293 
pain being the predominant symptoms. Several case reports and a small, prospective, open-294 
label phase II trial of tocilizumab in patients with PMR suggested that this drug might have a 295 
steroid-sparing effect. 130, 131 Another prospective open-label study found tocilizumab 296 
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monotherapy to be effective in new-onset PMR.132 Additional trials of IL-6 pathway 297 
inhibition in PMR are ongoing, including phase III trials of tocilizumab and sarilumab.133,134 298 
 299 
[H1] IL-6 inhibition in CRS 300 
Tocilizumab was approved by the FDA (in 2017) and EMA (in 2018) for the treatment of 301 
severe or life threatening chimeric antigen receptor (CAR) T cell-induced cytokine release 302 
syndrome (CRS) in adults and children. CAR T cells are ex vivo modified T cells from 303 
patients with cancer, which are reprogrammed to lyse tumour cells when bound to a specific 304 
cancer cell surface protein. However, ~70% of patients treated with a CD19 CAR T cell 305 
therapy develop CRS. 135 CRS leads to headache, fever, chills, severe nausea, vomiting, 306 
diarrhoea, musculoskeletal pain, dyspnea, hypotension and tachycardia, and in severe cases 307 
can be fatal. The approval of tocilizumab for the treatment of CAR T cell-induced CRS was 308 
based on retrospective analysis of data showing the efficacy of tocilizumab treatment in 309 
patients who developed CRS after CAR T cell therapy in prospective clinical trials. 136-138  310 
 311 
[H1] Other potential indications 312 
Unraveling the therapeutic potential of IL-6 pathway inhibition for indications other than 313 
those discussed above is a matter of ongoing basic and clinical research spanning various 314 
therapeutic areas. 4,5 Several investigator-initiated studies are either planned or ongoing or 315 
have already been published as proof-of-concept studies. A detailed representation of all of 316 
these studies is beyond the scope of this article but briefly, they encompass conditions such as 317 
uveitis, thyroid-eye disease, neuromyelitis optica, graft-versus-host disease, erosive hand 318 
osteoarthrtitis, various oncological indications, depression, schizophrenia, Schnitzler 319 
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syndrome, myocardial infarction, familial Mediterranean fever, COVID-19 pneumonia 320 
(caused by the novel coronavirus SARS-CoV-2) [Au:OK?Yes] and others.5, 139, 140 It is hoped 321 
that findings from some of these studies will expand the application and medical value of IL-322 
6 pathway inhibition to additional diseases in the future. 323 
 324 
[H1] Safety of IL-6 inhibition 325 
The safety profile of IL-6R inhibition is derived mainly from clinical trials of tocilizumab 326 
and sarilumab, as well as data from real-world registries of more than 1 million patients 327 
worldwide who have been treated with tocilizumab, including patients with RA, JIA and 328 
GCA. 26, 53, 141-164  329 
Consistent with expectations for a biologic DMARD for RA, serious infections, including 330 
bacterial serious infections, are among the most common serious adverse events reported in 331 
clinical trials, post-marketing surveillance studies, short-term studies and open-label 332 
extension studies. The overall rate of serious infections in patients with long-term exposure to 333 
IL-6 pathway inhibitors is in line with rates seen in studies with a short duration of exposure. 334 
58, 142, 156, 158, 161-166  335 
Treatment with IL-6 pathway inhibitors has been associated with elevations in serum 336 
concentrations of transaminases. These elevations did not seem to result in permanent or 337 
clinically evident hepatic injury in clinical trials. An increased frequency and magnitude of 338 
transaminase elevations was observed when potentially hepatotoxic drugs (for example, 339 
methotrexate) were used in combination with IL-6 pathway inhibitors. 161-164  340 
Pancreatitis is among the adverse reactions identified during post-approval use of tocilizumab 341 
and sarilumab161, 163 Gastrointestinal perforations have also been associated with use of these 342 
drugs; most such events occurred in patients with pre-existing risk factors (such as pre-343 
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existing diverticulitis or use of oral glucocorticoids); thus, IL-6 pathway inhibitors should be 344 
used with caution in patients with a history of gastrointestinal perforation, intestinal ulcers or 345 
diverticulitis. The overall rate of gastrointestinal perforations in populations with long-term 346 
exposure was in line with rates seen in short-duration studies. 26, 161-164  347 
Monitoring of lipid profiles and treatment of hyperlipidemia according to clinical practice 348 
guidelines is recommended during treatment with IL-6 inhibitors, as IL-6 pathway inhibition 349 
is associated with increased serum lipid concentrations (LDL and triglycerides). 151, 153 350 
Interestingly, IL-6 inhibition modifies HDL lipoproteins towards an anti-inflammatory 351 
composition, thus the atherogenic index is unchanged [Au: edited sentence OK?Yes] .167-169 352 
In the ENTRACTE study, a head-to-head RCT comparing the cardiovascular safety of 353 
tocilizumab and the TNF inhibitor etanercept in RA, the rate of major adverse cardiovascular 354 
events was similar with both treatments (HR 1.05, 95% CI 0.77–1.43). 170 355 
One safety concern of biologic therapies is the development of anti-drug antibodies, which 356 
can lead to loss of efficacy and/or immune-mediated adverse reactions.171 A study evaluating 357 
the immunogenicity of tocilizumab in patients with RA found that the incidence of anti-358 
tocilizumab antibodies was low [Au: Study description added, edit OK? Yes], regardless 359 
of the route of administration of tocilizumab or whether it was used as monotherapy or in 360 
combination with csDMARDs; moreover, anti-tocilizumab antibodies were mostly transient, 361 
and their development did not correlate with pharmacokinetics, safety events or loss of 362 
efficacy. 171 363 
For sirukumab, the FDA declined to approve the drug for use in RA owing to concern about 364 
an imbalance in all-cause mortality between the sirukumab and placebo groups in phase III 365 
studies, although whether this imbalance was a true safety signal or a result of the study 366 
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design is unclear. 172 Additional studies are needed to further define the safety profile of 367 
sirukumab. 368 
In general, monitoring for adverse events should always follow local labels, which are 369 
continuously updated with the latest safety information. 161-164  370 
 371 
[H1] Conclusions  372 
Substantial advances have been made in translating the biology of IL-6 to the treatment of 373 
patients with autoimmune diseases. Accumulating safety data on IL-6 pathway inhibitors 374 
have provided clinicians with the necessary knowledge for assessing the risk of using them. 375 
IL-6 pathway inhibitors have shown benefit in patients with RA, JIA, AOSD, GCA, 376 
Castleman’s diseases and CRS, and might also be beneficial in patients with other 377 
autoimmune diseases and even beyond. However, the limitations of preclinical studies for 378 
predicting clinical success in patients is a major barrier and necessitates early human proof-379 
of-concept studies. Case reports or series have proved useful in some conditions such as 380 
GCA, Takayasu arteritis, AOSD and CRS. In the future, trials to assess the efficacy and 381 
safety of a specific treatment within a biomarker-positive subgroup in heterogeneous patient 382 
populations (for example, a basket trial) to confirm and generate hypotheses might be an 383 
option. However, a reliable biomarker for predicting treatment response in many rheumatic 384 
diseases has not been identified.  385 
Several questions relating to IL-6 biology remain unanswered. For example, why does IL-6 386 
over-production occur and why does IL-6 signal inhibition lead to clinical meaningful 387 
benefits for patients with some diseases associated with IL-6 over-production (such as RA) 388 
but not all (such as AS)? Answering these questions would help to further progress our 389 
understanding of how various autoimmune diseases are regulated in the context of IL-6 390 
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pathway biology and help in developing additional, personalized treatment options for 391 
individual patients or patient subgroups. It seems that the journey of realizing the therapeutic 392 
potential of IL-6 pathway inhibition is far from over. 393 
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Table 1. Evidence for the effects of IL-6 inhibition on diseases.  965 
 966 
  967 
 968 
Disease  Cell based 
assays 
Animal 
models 
Biomarker
s 
 
Clinical 
trials 
Drug(s) 
indicated  
Multiple 
myeloma  
IL-6 
promotes 
myeloma cell 
proliferation 
13 
In the 
KPMM2 
xenograft 
model, 
growth is 
IL-6-
dependent 
173 
Serum 
concentratio
ns of IL-6 
correlate 
with disease 
severity in 
plasma cell 
leukemia 174 
No 
improveme
nt in 
clinical 
outcomes 
14, 16 
None 
Crohn’s 
disease  
IL-6 activates 
mucosal T 
cells175 
IL-6R 
blockade 
promotes 
T cell 
apoptosis, 
which 
contribute
s chronic 
intestinal 
inflammat
ion in the 
CD4 
adoptive 
transfer 
colitis 
model 175 
Serum 
concentratio
ns of sIL-
6R are 
increased in 
active 
disease24 
Concentrati
ons of IL-6 
and sIL-6R 
are 
increased in 
colonic 
organ 
cultures 
using 
specimens 
from 
patients 
with active 
disease176  
Tocilizuma
b had a 
clinical 
effect in a 
pilot 
study25  
None 
Castleman’s 
disease 
IL-6 is 
produced by 
affected 
germinal 
centres17  
IL6 
transgenic 
mice 
develop 
clinical 
features 
of 
Increased 
serum 
concentratio
ns of IL-6 
in active 
disease17 
Tocilizuma
b and 
siltuximab 
showed 
efficacy in 
Tocilizuma
b 
Siltuximab 
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Castlema
n’s 
disease19  
 
clinical 
studies22,23  
RA IL-6 involved 
in 
osteoporosis, 
cartilage 
destruction 
and synovial 
inflammation 
associated 
with RA27-29  
IL-6 
inhibition 
prevented 
developm
ent of 
arthritis in 
CIA 31, 32 
and 
AIA 33  
 
 
Serum 
concentratio
ns of IL-6 
elevated in 
active RA 
IL-6 
pathway 
inhibition 
effective in 
many 
clinical 
trials36-52, 
54-57, 62  
Tocilizuma
b 
Sarilumab 
 
Systemic JIA Increased 
production of 
IL-6 by 
PBMCs177 
IL6 
transgenic 
mice 
develop a 
skeletal 
phenotype 
resemblin
g 
abnormali
ties 
observed 
in 
children 
with 
chronic 
inflammat
ory 
diseases 
84  
 
Serum 
concentratio
ns of IL-6 
increased in 
patients 
with JIA 
and 
correlate 
with disease 
activity81, 
178  
Tocilizuma
b improved 
disease 
activity 
and 
reversed 
growth 
retardation 
86-91, 93, 95, 
179  
Tocilizuma
b 
 
Adult-onset 
Still's disease 
NA NA Serum 
concentratio
ns of IL-6 
increased180  
Tocilizuma
b showed 
some 
clinical 
benefit and 
steroid-
Tocilizuma
b  
 
 
33 
 
sparing 
effects94  
Ankylosing 
spondylitis 
NA NA Serum 
concentratio
ns of IL-6 
are 
increased 
and 
correlate 
with disease 
activity102  
Tocilizuma
b and 
sarilumab 
failed to 
show 
therapeutic 
benefit in 
RCTs 
103,104 
None 
Psoriatic 
arthritis 
NA NA Serum and 
synovial 
fluid 
concentratio
ns of IL-6 
increased106 
107 
Clazakizu
mab 
improved 
arthritis, 
enthesitis, 
and 
dactylitis 
but not 
skin 
disease108  
None 
SLE Increased 
production of 
IL-6 by B 
cells181  
IL-6 
implicate
d in 
autoimmu
ne disease 
pathogene
sis in 
NZB/W 
F1 mice 
109 
IL-6 
concentratio
ns increased 
in 
cerebrospin
al fluid110 
IL-6 
pathway 
inhibition 
affected 
autoantibo
dy-
producing 
cells but 
no 
clinically 
meaningful 
benefit 
demonstrat
ed112, 113 
None 
Systemic 
sclerosis 
Increased 
production of 
IL-6 by 
PBMCs182 
IL-6 
blockade 
improved 
disease in 
the 
bleomyci
Production 
of IL-6 
increased in 
dermal 
fibroblasts 
and serum 
concentratio
ns of IL-6 
Tocilizuma
b had a 
potentially 
clinically 
important 
effect on 
preservatio
n of lung 
None 
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  969 
 970 
 971 
 972 
 973 
 974 
 975 
 976 
n mouse 
model116 
increased117, 
118 
function120, 
121 
Giant cell 
arteritis 
NA NA Serum 
concentratio
ns of IL-6 
increased in 
active 
disease124 
Tocilizuma
b was 
superior to 
placebo 
with regard 
to 
sustained 
glucocortic
oid-free 
remission 
126, 127 
Tocilizuma
b 
 
Takayasu 
arteritis 
NA NA Serum 
concentratio
ns of IL-6 
increased in 
active 
disease125  
Tocilizuma
b had some 
effect on 
time to 
relapse but 
primary 
end point 
not met129 
Tocilizuma
b 
CRS NA NA Serum 
concentratio
ns of IL-6 
increased136 
Tocilizuma
b used 
successfull
y to treat 
CRS 
occurring 
in trials of 
CAR-T 
cell 
therapy136, 
137  
Tocilizuma
b 
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AIA, antibody-induced arthritis; CIA: collagen induced arthritis; CRS, cytokine release 977 
syndrome; JIA, juvenile idiopathic arthritis; NA, not available; PBMC, peripheral blood 978 
mononuclear cell; RA, rheumatoid arthritis; sIL-6R, soluble IL-6 receptor; SLE, systemic 979 
lupus erythematosus. 980 
 981 
Figure legend  982 
Figure 1: Timeline of the discovery of IL-6 and IL-6-targeted therapies. 983 
The timeline shows progress in the field if IL-6 pathway inhibition following the initial 984 
identification of a B cell stimulation factor in 1976, and the more definitive biochemical and 985 
molecular studies done in the 1980s and 1990s, to clinical trials and approvals in various 986 
diseases in 2000s and to the present day. AOSD: adult onset Still’s disease; AS: ankylosing 987 
spondylitis; CRS: cytokine release syndrome; GCA: giant cell arteritis; gp130, glycoprotein 988 
130; IL-6R, IL-6 receptor; LVV, large vessel vasculitis; pJIA: polyarticular course juvenile 989 
idiopathic arthritis, RA, rheumatoid arthritis; SSc: systemic sclerosis; sJIA: systemic juvenile 990 
idiopathic arthritis; SLE: systemic lupus erythematosus; Takayasu arteritis. 991 
 992 
Figure 2: Cell signalling pathways and physiological role of IL-6 in diseases. 993 
 994 
IL-6 participates in a broad spectrum of biological events, such as synovial inflammation, 995 
immune responses, haematopoiesis and acute-phase reactions [Au: Is this sentence in the 996 
right place?Yes] . (a) IL-6 binds to IL-6 receptor (IL-6R) and glycoprotein 130 (gp130) to 997 
form a hexameric complex. Both membrane-bound IL-6R and soluble IL-6R (sIL-6R) can be 998 
part of the hexameric complex, and are associated with the classical and trans signalling 999 
pathways, respectively. Intracellular signalling pathways involve the Janus kinase (JAK) and 1000 
signal transducer and activator of transcription (STAT) pathway. Pharmacological inhibitors 1001 
of IL-6 signalling prevents IL-6 from binding to IL-6R by targeting either the cytokine itself 1002 
or the receptor. 1003 
(b) In the context of disease, IL-6 can have both local inflammatory and systemic effects. 1004 
Some of the manifestations of the diseases for which IL-6 inhibitors are approved could be 1005 
explained by the effects of IL-6, on the basis of both preclinical and clinical data. IL-6 has 1006 
been implicated in the pathogenesis of diseases including rheumatoid arthritis, systemic 1007 
juvenile idiopathic arthritis (sJIA), Castleman’s disease, giant cell arteritis, Takayasu arteritis 1008 
and cytokine release syndrome, among others (c) [Au: If there will be a third part to this 1009 
figure, please provide the details (i.e. sketch and legend) via email, thanks by email]  1010 
CRP, C-reactive protein; MMP, matrix metalloprotease; RANKL, receptor activator of NF-1011 
κB ligand; SAA, serum amyloid A; VEGF, vascular endothelial growth factor.  1012 
 1013 
 1014 
